Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Emami Effort For Zandu Shares Reaches Indian High Court

This article was originally published in PharmAsia News

Executive Summary

One set of Zandu Pharmaceuticals promoters has petitioned the Bombay High Court to block Emami's effort to buy shares of the company from other Zandu promoters. The Parikh family based in Mumbai took the action against the Vaidyas group, but Zandu's chairman is trying to iron out the dispute. Y.P. Trevidi said he has asked both parties to resolve their differences out of court. The Parikhs, who own nearly a 25 percent stake in Zandu, filed the court action after failing to obtain a stay of Emami's acquisition offer, claiming they have the right of first refusal. (Click here for more

You may also be interested in...

China Still Alluring? AZ, Pfizer Feel COVID Pinch, New Pricing Scheme Clouds Outlook

Despite leading multinational pharma firms including AstraZeneca again delivering double-digit growth in China, the impact of coronavirus and an expanding volume-based purchasing scheme begin to surface.

Coronavirus Update: BioNTech And Fosun Launch Vaccine Trial In China

The study is designed to support the regulatory approval process in China and confirm that the safety and immunogenicity profile observed in German and US trials is comparable to that of Chinese participants, according to BioNTech.

QUOTED. 6 August 2020. Department of Health and Social Care.

The UK Department of Health and Social Care recently asked medical device and pharmaceutical companies to establish contingency measures in case of supply problems post-Brexit.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts